November 2025 in “Journal of Investigative Dermatology” Certain CD8+ T cells attack hair follicles in alopecia areata, suggesting they could be targeted for treatment.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” In this study, researchers used a mouse model of alopecia areata to demonstrate that both ruxolitinib and baricitinib, oral JAK inhibitors, reduced hair loss, CD8+ cell infiltration, and expression of disease-related markers, with baricitinib showing greater effectiveness.
August 2024 in “Current Protocols” In this study, researchers described protocols using C3H/HeJ mice to reliably induce alopecia areata through full-thickness skin grafts or adoptive transfer of cultured lymphoid cells, offering valuable models for studying the disease and testing new drug therapies.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” This study reports that CD200R expression is significantly reduced in an experimental mouse model of scarring alopecia, suggesting a potential role for this pathway in immune regulation and hair follicle protection.
April 2026 in “Journal of Pharmaceutical and BioTech Industry” This review highlights recent advances in personalized transdermal drug delivery systems, noting their potential for improved treatment efficacy and safety, but identifies significant challenges in clinical translation.